Board of Directors
Board of Directors

Corporate Governance

Douglas J. Swirsky, Chairman of the Board

Mr. Swirsky serves as Fibrocell’s Chairman of the Board. He has served as a member of our Board since March 2013. Mr. Swirsky currently serves as President and Chief Executive Officer of Rexahn Pharmaceuticals, Inc., a publicly-traded clinical-stage oncology company. Prior to joining Rexahn, Mr. Swirsky served as President, Chief Executive Officer, and a Director of GenVec, Inc., a publicly traded biotechnology company; a position he held from 2013 through the sale of the company in June 2017. Mr. Swirsky joined GenVec in 2006 as Senior Vice President, Chief Financial Officer, Treasurer and Corporate Secretary. Prior to joining GenVec, Mr. Swirsky worked at Stifel Nicolaus where he served as a Managing Director and the Head of Life Sciences Investment Banking. Mr. Swirsky previously held investment banking positions at UBS, PaineWebber, Morgan Stanley, and Legg Mason. His experience also includes positions in public accounting and consulting. Mr. Swirsky is the Chairman of the Board of Directors of Cellectar Biosciences, Inc.  He received his B.S. in Business Administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. Mr. Swirsky is a Certified Public Accountant and a CFA® charterholder.

Julian P. Kirk, Director

Mr. Kirk has served as a member of our Board since October 2012. Mr. Kirk is a Managing Director of Third Security, LLC, where he has worked since the firm’s inception with several portfolio companies of its managed investment funds. He is also involved with the oversight of Third Security, LLC’s internal operations. Mr. Kirk was a member of the board of directors of AmpliPhi Biosciences Corporation (NYSE: APHB) from June 2013 to April 2015. From August 2010 to June 2019, he served on the board of the New River Valley Economic Development Alliance. From October 2006 until December 2011, he served as a member of the board of directors of IntelliMat, Inc. and as Co-Chairman of its board of directors between September 2008 and December 2011. From September 2005 until December 2011, Mr. Kirk served as President of Harvest Pharmaceuticals Inc. Mr. Kirk also served as Chairman of the board of managers of ECDS, LLC from June 2008 until March 2010. Mr. Kirk graduated as an Echols Scholar from the University of Virginia.

John Maslowski, Director

Mr. Maslowski has served as a member of our Board since December 2016. Mr. Maslowski is Fibrocell’s President and Chief Executive Officer. Prior to that, he was Senior Vice President of Scientific Affairs, with oversight of research and development, clinical and regulatory affairs. Previously, he was Vice President of Operations with responsibility for manufacturing and quality operations. Prior to joining Fibrocell, Mr. Maslowski held various positions at Wyeth Pharmaceuticals, Inc. (now Pfizer, Inc.), eventually serving as Quality Assurance Manager. Prior to joining Wyeth, Mr. Maslowski held various positions with Merck & Co. and Teva. Mr. Maslowski earned a B.S. in Biology from the Ursinus College and an M.S. in Biology from Villanova University.

Marc B. Mazur, Director

Mr. Mazur has served as a member of our Board since April 2010. Mr. Mazur currently serves as an executive advisor to Brightwood Capital Advisors, a $4 billion private credit fund. Previously, Mr. Mazur served as the Chief Executive Officer of Brevan Howard U.S. Asset Management. Mr. Mazur held management positions at Salomon Brothers, Goldman Sachs and Swiss Bank Corporation. He is a member of the board and audit chair of GSV Capital, a public business development company, and a member of the board of GX Acquisition Corporation, a publicly-listed, special purpose acquisition company. He has served on a number of private company boards in the wellness, population health and medical device fields. Mr. Mazur received his B.A. in political science from Columbia University and a J.D. from Villanova University School of Law.

Kelvin D. Moore, Director

Mr. Moore has served as a member of our Board since 2009, including several years as lead independent director and as chair of the compensation committee since 2010. He has 30 years of experience in the banking sector with NatWest (now Royal Bank of Scotland) working in executive leadership roles in lending and internal strategic consultancy, and also as Head of Fast Track Executive Recruitment and Development, Head of Business Education, Senior Strategist of Private Banking (Coutts’ Bank) and as a board director for a wholly-owned subsidiary dealing with internet start-up businesses. Mr. Moore is an independent business strategist and mentor for executives with expertise in commercial construction, social media, business development and sales, and skin correction treatments. He holds a London University Degree in Geography and Pure Mathematics and has completed additional coursework at both UK and European Business Schools, including an Oxford University Summer Economics Course.

Marcus E. Smith, Director

Mr. Smith has served as a member of our Board since October 2012. Mr. Smith joined Third Security, LLC upon its inception and serves as the company’s Senior Managing Director, General Counsel and Chief Compliance Officer with principal responsibility for legal matters and transaction execution. From August 1996 to April 2004, Mr. Smith served as Senior Vice President, General Counsel, Secretary and member of the board of directors of New River Pharmaceuticals Inc. Mr. Smith received his B.B.A. and his J.D. from the University of Georgia.

Christine St.Clare, Director

Ms. Christine St.Clare has served as a member of our Board since February 2013. Her career spans 35-years with KPMG LLP, where she served a four-year term on the firm’s board of directors and chaired the board’s audit and finance committee. Currently, in addition to being a member of Fibrocell’s board of directors and chairing its audit committee, Ms. St.Clare is on the board of directors of AquaBounty Technologies, Inc., and chairs its audit committee. Furthermore, she is a member of the board of directors of Tilray, Inc. and serves as chair of its audit committee and a member of the nominating and governance committee. She served on the board of directors of Polymer Group, Inc. and as the chair of its audit committee until the company was sold in October 2015. Ms. St.Clare recently served on advisory boards of Houlihan Lokey, a midsize global, advisory-focused investment bank, Women Corporate Directors, and Emory University’s Goizueta Business School. In April 2019, Ms. St.Clare was recognized by the National Association of Corporate Directors (NACD) as an honoree of the 2019 NACD Directorship 100, a list of the most influential leaders in the boardroom and corporate governance community. Ms. St.Clare earned a B.S. in Accounting from California State University at Long Beach.